Core Delivers, Lithium Delays; The Margin Question Lingers
Q2 revenue and PAT soared on a YoY basis—21% and 65% respectively—validating management's core growth narrative. But sequentially, profit fell 18%, margins missed guidance by 150 bps, and the lithium ramp slipped to Q4/FY28. The tension: solid momentum offset by near-term headwinds.
₹5,292 Cr
+21.2% YoY; -4.3% QoQ
₹287 Cr
+65.4% YoY; -18.3% QoQ
12.1%
+130 bps YoY
10.6%
vs 12–12.5% guided
The year-on-year numbers paint a confident picture. Core battery revenue is up 21%; profit up 65%. Exide's core business is firing—OEM traction strong, pricing power holding, exports ramping. Management's mid-double-digit growth guidance is not just met; it's credibly beaten. But a quarter is not a year. Sequentially, revenue fell 4%, profit fell 18%, and operating margin came in 150 bps below the stated 12–12.5% corridor. The lithium-ion ramp, positioned as the long-term growth engine, has slipped from implicit prior expectations into Q4/FY28. Strip away the momentum narrative and you see a company managing near-term margin pressure, sequential cyclicality, and execution risk on a ₹5,352 Crore investment that hasn't yet moved the needle on earnings.
The Core Business Delivered; Margins Didn't
EBITDA margin expanded 130 bps YoY to 12.1%, a headline-friendly number. But the delivered OPM of 10.6% against a stated corridor of 12–12.5% tells a different story. Management's explanation: price hikes announced in January and October have not yet flowed through. Lead and LME prices remain elevated; crude oil spiked (pushing separator costs); the rupee weakened. The lag between input spikes and pricing pass-through is typically one to two quarters. This means Q3 and Q4 could see margin pressure if commodities don't ease—and management has already hedged expectations, saying the corridor is a range, with some quarters at the lower end. The company is signalling it will remain within 12–12.5%, but not necessarily comfortable within it.
Lithium: The Future, Deferred
Exide's 6 GWh lithium-ion plant came live in September 2026—on schedule. Two lines are operational: a 1.5 GWh NMC cell line and a 1.5 GWh LFP line. The company is now in sample and validation phase with multiple OEM partners (Tata Siern, MG, auxiliary battery suppliers, unnamed telecom players). But the critical issue is timing: management deferred major OEM production ramp to Q4 FY27 (January–March) or Q1 FY28 (April–June). This is a material slip from implicit prior expectations. Worse, the MD clarified that OEM lifecycle testing cycles run 2–3 years, and once lifecycle is complete, customers conduct pack-level and vehicle-level testing. Translation: the ₹1,400 Crore capex spend is now a 2–3 year story for ROI, not a 1–2 year one. On the call, analysts pressed hard on lithium margins, capex payback, and phase-2 timing. Management deferred all quantified guidance to the next quarter, citing pending board approval. The takeaway: Exide is building lithium at scale, but the money won't move the needle on earnings until late FY28 at earliest.
Core business delivered mid-double-digit growth
Q2 revenue +21.2% YoY (H1 +18.9% YoY). Claim supported.
Supported
EBITDA margin expanded 130 bps to 12.1%
Delivered 12.1% EBITDA margin; but OPM only 10.6% vs 12–12.5% guided corridor.
Partially overstated
Margin corridor target 12–12.5% will be maintained
Q2 OPM 10.6% missed. MD now hedges: 'some quarters lower, some higher' within corridor.
Contradicted
Lithium revenue will materialize Q4 FY27 / Q1 FY28 for major OEMs
Small OEM samples Q3; major OEM production ramp deferred to Q4/Feb (pushed 2–3 quarters from prior implicit timeline).
Supported (but delayed)
Auto OEM business +25% for fourth consecutive quarter
Q2 overall revenue +21.2% YoY; OEM segment not separately broken out in result. Directional claim credible.
Supported
What Changed on This Call
Lithium timeline slipped. Prior expectation was implicit Q1/Q2 FY28 major OEM ramp. Now it's deferred to Q4/Q1, with lifecycle testing cycles running 2–3 years. Execution risk elevated; revenue materialization pushed into late FY28 or FY29. Core business momentum confirmed. Mid-double-digit growth guidance met; Q2 delivered 21.2% YoY, with automotive OEM +25% for four consecutive quarters. No surprise on the upside, but the track record is now credible. Margin corridor narrowed by execution gap. Stated 12–12.5% target narrowed to 'a range' with some quarters lower. Q2 OPM 10.6% signals management is comfortable missing the high end if input costs persist. Capex guidance deferred. No FY27/FY28 capex specifics given; management cited pending board approval. Phase-2 12 GWh capex decision deferred to when phase-1 hits 80% utilization (2–3 years hence). This removes a near-term upside catalyst.
Core revenue +21% YoY; 4Q OEM growth +25% validates momentum
EBITDA margin +130 bps YoY; pricing power demonstrated
Balance sheet debt-free; strong cash generation for capex & investment
Q2 profit -18% QoQ; sequential softness not fully explained
OPM 10.6% vs 12–12.5% guided; margin corridor miss signals persistence of input lag
Lithium ramp slipped 2–3 quarters; major OEM revenue now Q4/Q1 FY28 or later
₹5,352 Cr cumulative lithium investment; no quantified margin or ROI guidance given
Capex guidance deferred; phase-2 decision 2–3 years away
Lithium execution & validation delays
High6 GWh plant live, but lifecycle testing is 2–3 years. Major OEM ramp now Q4/Q1 FY28 or later. If testing fails or customer wins slip further, the ₹5,352 Cr investment will take 4+ years to move the needle on earnings, or mark-to-market if demand disappoints.
Input cost volatility & pricing lag
HighLead, LME, crude oil, rupee all remain volatile. Price hikes lag input spikes by 1–2 quarters. Q2 OPM 10.6% misses guided 12–12.5% target. If commodities stay elevated through H2, margin recovery is unlikely; further compression possible.
Sequential demand softness & cyclicality
MediumQ2 revenue -4.3% QoQ, PAT -18% QoQ. Management blamed GST normalization but didn't rule out seasonal patterns repeating. Q3 could also soften. Lumpy order patterns in automotive (new model launches, OEM ordering cycles) and government tenders (railways, power) create visibility gaps.
China raw material supply disruption
MediumLithium hydroxide, cobalt exports from China could face restrictions. Exide planning 3-month inventory buffer, but higher holding could strain working capital. Supply-chain localization to 50–60% BoM target is 2–3 year roadmap; interim period carries supply risk.
Lead-acid volume decline as EV penetration accelerates
MediumTwo-wheeler & three-wheeler EV sales growing 30%+ CAGR. Lead-acid remains dominant for ICE parc (3–6 year replacement cycle), but structural volume headwinds will accelerate. Core business growth rate will decelerate over 3–5 years unless lithium offsets the decline.
How the Market is Positioned
The stock is down 38% from its all-time high of ₹620.35, now trading at ₹385.05. On the result announcement (Nov 4), the stock fell 1.6% on day 1 (delivery 78.2% of volume), then rebounded +4.52% by day 3. The rebound held, suggesting the market accepted the earnings narrative after initial disappointment. However, the stock remains below its 50-day simple moving average (₹393.82) and neutral in trend (RSI 56.6, between 40 and 70). Relative to the 52-week range (₹287–₹496.4), the stock is off its lows (+34% from low) but well below its highs (−37% from ATH). Ownership data shows FII holding stable at 10.63% (up +0.33pp QoQ) and DII at 19.30% (up +0.17pp QoQ), suggesting institutional appetite is cautious but not fleeing. Promoter holding remains at 45.99% with no change. The muted institutional activity suggests the market is waiting for lithium to prove out before re-engaging; the near-term narrative is one of core execution and margin recovery, not growth inflection.
What to Watch Next
1 · Q3 FY27 lithium small-OEM ramp & sample validation updates (Dec 2026)
Exide expects small OEM samples to be live by November/December. NMC lifecycle testing progress and LFP traction with emerging 2W players will be key. Any delays or customer feedback issues will further defer major OEM ramp.
2 · Major OEM lithium cell production ramp timing (Q4 FY27 or Q1 FY28)
Management guided Q4 or February for first major OEM production launches. This is the inflection point for lithium revenue materialization. Slippage beyond Q1 FY28 will reset the 2–3 year lithium timeline further out.
3 · H2 FY27 margin trajectory & lead/rupee stabilisation (Oct–Mar 2027)
Price hikes should begin flowing through by Q3. If input costs ease and pricing sticks, OPM could climb back toward 12% by H2. This will validate management's corridor guidance. If commodities remain sticky or pricing power wanes, the 10.6% could persist or compress further.
4 · Phase-2 12 GWh capex board decision & timing (FY27/FY28)
Management deferred phase-2 capex guidance to 'next quarter'. The trigger for phase-2 capex approval is 80% phase-1 utilization (2–3 years away per MD). Early signal on this timeline will clarify long-term lithium ambitions.
Exide's Q2 is a study in how momentum and margin can diverge. The core business is healthy—21% revenue growth, strong OEM traction, pricing power intact. But margin miss (150 bps below guided corridor), sequential profit decline (18% QoQ), and lithium timing slip (2–3 quarters deferred) temper the growth narrative. The market has priced in these risks; the stock is down 38% from its highs, and institutional flows are flat. The next 18 months are about margin recovery and core execution; the lithium inflection is 2–3 years out. Until lithium becomes a material revenue contributor, Exide is a steady-state battery play with event risk on execution and cyclical margin pressure. The number to track: operating margin. If Q3/Q4 FY27 OPM climbs back into the 12–12.5% corridor on the back of price hikes and input cost stabilisation, the near-term risk is contained. If it compresses further, the debate shifts from lithium timing to core business durability.
Battery Ramp Enters Sampling Phase—Core Business Steady
Exide's Q1 set a strong baseline with 27% PAT growth and early lithium cell commissioning. Q2 watch list: whether margin momentum holds as EESL transitions from build to customer sampling, and how much lead-acid volume accelerated vs expectations.
What to Expect
Exide enters Q2 from a position of unusual strength. Q1 FY27 delivered ₹5,528 Cr consolidated revenue (+17.7% YoY) and ₹351 Cr net profit (+27.9% YoY)—a rare beat where profit outpaced topline growth. The driver: higher realization in lead-acid batteries and leverage from earlier pricing actions. On plan for Q2 would mean sustained mid-teens revenue growth (12–16% YoY) anchored to auto sector demand and aftermarket battery replacement cycles, with profit growth tracking at the high end of guidance if margins hold.
~₹5,300–5,500 Cr
12–16% YoY growth; tracking run-rate from Q1 (₹5.5k Cr basis)
~₹340–370 Cr
on-plan at 20–25% YoY if margins hold; Q1 set 6.3% net margin
Pre-revenue
6 GWh lithium facility commissioned; sampling phase expected Q1 FY27 per guidance
Lead-acid mix & volume
Industrial/EV battery demand vs auto OEM production; automotive sector softness would pressure growth
A strong Q2 print would show: (1) revenue holding above ₹5.3 Cr with auto OEM demand resilient and aftermarket cycles intact; (2) gross margin stable or higher on continued pricing discipline; (3) PAT growth ≥20% YoY, proving the Q1 margin lift was structural not transient; (4) management guidance reaffirmed or raised for full-year ₹20k Cr revenue arc. A weak Q2 would signal: (1) automotive production headwinds pushing volume lower despite pricing; (2) EESL capex drag on standalone margins ahead of revenue; (3) margin compression from mix shift if higher volumes come only from lower-margin segments; (4) any revision down to full-year guidance.
Tracking the Guidance
Management has signalled a 3-year path to ₹20,000 Cr revenue (from FY27 base of ~₹22 Cr run-rate annualized) and ₹25,000 Cr by 2030, anchored to EESL scaling. The FY27 capex of ₹1,400 Cr into lithium-ion is front-loaded (₹550 Cr invested in the last 90 days alone), positioning the subsidiary to move from construction to commissioning to early production this fiscal. Crucially, management has withheld margin and ROCE guidance until utilization reaches 80%+—a signal that the next 2–3 years will be investment-heavy on the P&L. Q2 will be the first print where this capex intensity shows cleanly in the numbers.
Street View
Since Last Quarter—Key Filings
1 · EESL capital infusion sprint (Sep–Oct 2026)
Parent invested ₹550 Cr into subsidiary across four tranches (₹100 Cr Jul 15, ₹200 Cr Aug 18, ₹100 Cr Sep 29, ₹150 Cr Oct 27). Cumulative now ₹5,202 Cr. Non-dilutive to parent (rights basis); signals aggressive build schedule. Operationally positive but P&L drag unless EESL begins revenue recognition soon.
2 · Lithium facility commissioned (Sep 23)
6 GWh Phase-I lithium-ion cell facility at Devanahalli, Bengaluru now operational. Cylindrical cell lines expected to begin customer sampling by Q1 FY27; prismatic lines to follow. No P&L contribution yet, but de-risks the execution timeline.
3 · European battery JV announced (Sep 16)
Long-term cooperation pact signed with ExCom Energy Solutions GmbH (Germany) for industrial battery & energy storage. Strategic but non-material to Q2 numbers. Signals geographic diversification intent.
4 · Trading window closure (Aug 25)
Routine; no insider trades flagged.
The Valuation Puzzle
Stock is down 43% from ATH (₹620 in 2024) despite Q1 delivering a beat and lithium-ion assets de-risked. The discount reflects two real concerns: (1) visibility—EESL is still pre-revenue and margin guidance withheld; (2) near-term P&L pressure—₹1,400 Cr FY27 capex will show up as expense and working capital drag, pulling consolidated net margin lower. Street median of ₹378 offers only ~7% upside from ₹354 here, pricing in that capex cycle. A Q2 beat on profitability (margin ≥6.5% net) and any commentary on EESL timeline acceleration could rerate the stock higher.
What to Watch on Result Day
1 · Consolidated PAT margin
Q1 was 6.3% net margin. Expect 5.8–6.2% if capex drag shows. Below 5.5% would signal execution risk or automotive slowdown.
2 · Standalone vs consolidated split
EESL losses will dilute consolidated profit. Watch whether management provides segment P&L to isolate parent performance.
3 · Lead-acid volume and ASP
Pricing holds only if volume is resilient. Any mix deterioration toward lower-margin segments would explain margin miss.
4 · EESL sampling update
Exact timeline (Q4 vs Q1 FY27 for customer samples) and customer pipeline visibility. Absence of detail = execution concern.
5 · FY27 and 3-year guidance reaffirmed?
Any trim to the ₹20k Cr 3-year revenue target would reset Street expectations sharply downward.
Exide enters Q2 with strong Q1 momentum and a credible lithium-ion playbook, but valuation and sentiment suggest Street is pricing in 2+ years of capex-driven margin pressure before EESL scales. The Nov 4 result is less about the quarter's numbers and more about tone: does management believe the lithium transition is on track, or is there any wavering? On plan would be revenue in the ₹5.3–5.5k range and PAT margin holding above 6%, with no guidance cuts. Anything weaker opens the door for a test of the ₹300 analyst floor.
Strong core momentum, lithium scaling cautiously; margin corridor sustainable
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Core guidance (mid-double-digit growth) met; lithium capex on track (₹1,400 Cr approved). Margin corridor not met this quarter (10.6% vs 12–12.5% target). Lithium timing deferred vs implicit prior expectations.
Optimistic
next 1–2 quarters
Optimistic
multi-year
Exide's core battery business is firing on all cylinders—21% revenue growth, 65% PAT growth, strong OEM traction, and pricing power offsetting input costs. However, the lithium-ion ramp is a multi-quarter story, with major OEM revenue not expected until Q4 FY27 or Q1 FY28, materially delaying EPS accretion. Q2's 18% PAT decline sequentially and 10.6% OPM vs guided 12–12.5% signal margin compression risk persists despite price hikes. Near-term upside is solid, but lithium execution risk and input cost volatility warrant a cautious stance until lithium becomes a material contributor.
₹5291.9 Cr
Revenue · +21.2% YoY₹287.1 Cr
Reported PAT · +65.4% YoYCompressing
Margins · vs guidance: CorroboratedDid the claims hold up?
Core business delivered 20%+ YoY revenue growth in Q2
METReported Q2 revenue ₹5,292 Cr, +21.2% YoY (vs standalone ₹5,026 Cr +20.3% claim). Corroborated.
EBITDA margin expanded 130 bps YoY to 12.1% on calibrated pricing
OVERSTATEDQ2 EBITDA reported at ₹606 Cr, margin 12.1% vs 9.4% prior year. OPM delivered 10.6% (below stated 12–12.5% core corridor). Partially overstated.
PAT grew 65.4% YoY; half-year PAT up 46.5% YoY
METDelivered PAT ₹287.1 Cr, +65.4% YoY. Corroborated by strong margins and EBITDA growth.
Lithium will begin revenue generation in Q2 (starting October); major OEMs Q4/Q1 FY28
METCall explicitly deferred lithium revenue detail. MD cited validation timelines: small OEMs 'next month' (Nov), major OEMs 'Q4 or maybe February'. Cautious vs initial optimism.
Automotive OEM business grew 25%+ for fourth consecutive quarter
METClaim is directional. Q2 overall revenue +21.2%; OEM specifically not broken out in delivered results. Cannot directly verify but tone suggests credible.
Exports grew 20%+ YoY for second consecutive quarter on low base
METClaim supported by trajectory. Standalone H1 revenue growth 18.9% suggests export contribution material. Cannot isolate in delivered results.
Core business margin corridor will remain 12–12.5%; some quarters lower, some higher
MISSQ2 OPM delivered 10.6%, below corridor. Suggests either (1) core excludes non-core drag, or (2) input cost headwinds pushing below target. Management clarified price increases are ongoing but timing lags input spikes.
Earnings quality
What changed since the last call
Lithium ramp timeline
DowngradePrior: implicit Q1 FY27 entry. Now: small OEMs Q3, major OEMs Q4/Q1 FY28. De facto 2–3 quarter slip; execution risk flagged explicitly.
Core business growth momentum
UpgradePrior: mid-double-digit. Delivered: 21.2% YoY in Q2, 18.9% H1. Auto OEM +25% 4Q running. Guidance track record improved.
Capex phasing
NeutralFY27 ₹1,400 Cr lithium capex approved and on-track (6 GWh commissioned Sept). Phase-2 12 GWh expansion decision deferred to when utilization hits 80% (2–3 year timeline per MD).
Margin corridor sustainability
DowngradePrior: 12–12.5% core corridor. Delivered: 10.6% OPM in Q2 despite price hikes. MD now hedges: 'within corridor, but some quarters lower.' Margin recovery pushed into H2/FY28.
The Q&A
Analysts pressed hard on lithium timing, pricing dynamics, and capex ROI. Management held firm on core business strength but ceded ground on lithium: deferred revenue estimates to later quarters, detailed validation bottlenecks (OEM testing cycles, 2–3 year sample timelines), and flagged supply-chain localization as a multi-year task. No fireworks; disciplined pushback on competitive dynamics and capex payback avoided.
Lithium customer traction, sample cycle — Raghunandhan, Nuvama Wealth
PartialSample validation ongoing with leading 2W OEMs; lifecycle testing in progress. NMC: major OEMs Q4/February. LFP: started with 102 Ah cells. BESS: waiting for PLI clarity before manufacturing. Competitive engagement very structured.
Core lead-acid business margin trajectory — Vibhav Zutschi, JP Morgan
AnsweredWe are clearly within 12–12.5% corridor. Some quarters lower, some higher, depending on input cost cycle. October saw price hikes to pass through input inflation. For next two quarters, we will remain within the corridor.
Lithium NMC capacity and OEM launches — Vibhav Zutsshi, JP Morgan
AnsweredAvik: Small OEMs can start next month small qty. Major OEMs: Q4 or Feb. Pravin: For small customers, even next month in small qty. Major OEMs hoping Q4 or Feb.
Lithium cell pricing and import parity — Arvind Sharma, Citi
Partial5–10% cost gap vs. Chinese landed basis (form factor, chemistry). Negotiation-driven. Pricing indexed to lithium and local supply advantage/cost dynamics; strategic benefit of second local source. No hard rule.
Lithium BESS manufacturing, government incentive clarity — Jinnesh Gandhi, Oaklane Capital
PartialAvik: BESS line is line four on the plant. We will make multiple BESS products. Decision deferred pending PLI/government clarity. Line is ready; we will use it for BESS or other products. MD noted 60% local content req. (uncertain if AC or DC). Our focus: batteries & cells first; others secondary.
Lithium capex phase-2, decision point, margins outlook — Krupashankar N.J., Avendus
PartialAvik: Phase-2 capex (12 GWh) already approved. Land bought, utilities setup. Lead time will be lower than phase-1 (started greenfield). Decision on phase-2 expansion when utilization hits 80%. Rupee depreciation adding ~10% to equipment costs. On margins: no guidance yet on lithium margin. Will be dynamic. First: ramp revenue; margins follow operational excellence.
Lead-acid pricing and input cost hikes — Krupashankar N.J., Avendus
AnsweredAvik: Calibrated price increases taken Jan/Oct. ~10% overall in 2W, lesser in 4W, ~5% in 2W. OEM hikes also taken (outside lead formula). Cost optimization ongoing to absorb input headwinds. Will continue to take hikes step-by-step as costs rise.
Lithium vs. lead revenue mix by FY28 — Kevin Gandhi, CapGrow Capital
AnsweredAvik: No margin guidance on lithium yet. Will make it cash-neutral in 2–3 years. Full utilization 80% in 2–3 years at operational excellence. Beyond that: economics improve.
Capex and working capital for lithium phase-2 — Animesh Jain, Dalal & Broacha
AnsweredAvik: Capex phase-1 for 6 GWh is over. Phase-2 decision at 80% utilization. Working capital: already factored in annual budget (₹400–500 Cr depreciation on core). Inventory: 3-month hold due to China raw material delays/export license risk. Pravin: Long-term purchase agreements with suppliers ensure supply security.
FY27 FY28 capex and guidance update — Jinesh Gandhi, Oaklane
DodgedAvik: No, we have not yet presented to board. We roughly know it will be mostly for working capital, land, loss funding. Not much for capital equipment. We will come back next quarter with board-approved guidance.
Guidance
FY27 core business mid-double-digit growth momentum
HighQ2 delivered 21.2% YoY revenue growth; H1 at 18.9%. Auto OEM +25% 4Q straight; exports +20% consecutive quarters. Visibility strong through Q4 given order pipeline.
Lithium revenue materialization Q4 FY27 (niche OEMs) to Q1 FY28 (major OEMs)
MediumSmall OEM samples Q3 (Nov); major OEM production ramp Q4 (Jan–Mar) or Q1 FY28 (Apr–Jun). Validation cycle 2–3 years per MD. Initial volume guidance deferred. Risk: lifecycle testing delays.
Core business margin target 12–12.5% EBITDA corridor; flex within range based on input cost cycle
MediumQ2 delivered 12.1% EBITDA (within corridor on standalone basis); OPM 10.6% (below). Price hikes Jan/Oct offsetting input pressure but timing lag persists. H2 expected to remain within corridor.
Lithium cell margins not quantified; aim for cash-neutral in 2–3 years
LowMD: No margin guidance on lithium. Plan is to achieve cash-neutral breakeven in 2–3 years; beyond that, margins improve as utilization climbs. Operational excellence critical.
FY27 ₹1,400 Cr lithium capex approved; 6 GWh line commissioned Sept 2026
HighOn track. Capex spend in H1 reflects completion of phase-1. Phase-2 (12 GWh) land bought, utilities setup; decision at 80% phase-1 utilization (~2–3 years).
Core business capex ~₹400–500 Cr annually for depreciation maintenance + debottlenecking
HighOngoing productivity & automation capex on manufacturing lines. 'Debitlenecking' each factory to squeeze OEM/aftermarket volume without major new capex.
FY27/FY28 detailed capex plan to be presented to board; guidance deferred to next quarter
LowMD stated board approval pending. Roughly estimated: working capital, land, loss funding for lithium. Minimal capital equipment expected given 80% phase-2 utilization timeline.
Risks the call surfaced
Input cost volatility
HighLead (LME), LME antimony, crude oil (for separators), rupee fluctuation all inflate COGS. Q2 lead prices elevated; crude oil spikes; rupee weakness cited as headwinds. Price hikes lag input spikes by 1–2 quarters.
Lithium execution & validation
High6 GWh plant commissioned Sept; still in sample/validation phase. Major OEM production ramp deferred to Q4 FY27 or Q1 FY28 (2–3 quarters later than implicit prior expectation). Lifecycle testing cycles 2–3 years per OEM protocol. Risk of further delays if customer testing uncovers performance gaps.
Margin compression from input costs
MediumQ2 OPM 10.6% vs guided 12–12.5% corridor. Despite price hikes, margin compression from input costs not fully absorbed. Pricing lag 1–2 quarters means H2 could see further near-term pressure if commodities remain elevated.
Sequential demand softness
MediumQ2 saw -4.3% QoQ revenue decline and -18.3% PAT decline. Management attributed to GST normalization post-base-effect boom, but seasonal pattern suggests Q3 could also soften. Automotive segment demand lumpy.
China raw material supply disruption
MediumExport restrictions on lithium hydroxide, cobalt from China could disrupt EESL supplies. Management planning 3-month inventory buffer to hedge. Risk: higher working capital strain, potential shortage if restrictions escalate.
Management
Score 7/10. Transparent on core business metrics; detailed on lithium technical roadmap & constraints (validation cycles, capacity phasing). Deferred several specific targets (FY27/28 capex, lithium margins, phase-2 timing) to later quarters, citing board approval pending—reasonable but limits visibility. Core business guidance met (mid-double-digit growth achieved 21%+ in Q2). Lithium capex on-track (6 GWh commissioned Sept as planned). Margin corridor target missed Q2 (10.6% OPM vs 12–12.5%), but management candidly attributed to input cost lag and timing. Track record credible overall.
1 · Q3 FY27 (Dec 2026)
Lithium small-OEM revenue ramp; NMC validation updates from OEMs
2 · Q4 FY27 (Mar 2027)
Major OEM lithium cell orders & approvals; phase-2 capex board approval
3 · Q1 FY28 (Jun 2027)
First major OEM production ramp into 1.5 GWh NMC line; 12 GWh phase-2 timelines
Near-term upside is solid, but lithium execution risk and input cost volatility warrant a cautious stance until lithium becomes a material contributor.
Exide Q2 FY27: consolidated PAT up 65% YoY to ₹287 Cr as margins expand
PAT +65.37% YoY · revenue +21.25% · margins expanding
₹5,291.87 Cr
+21.25% YoY
₹287.14 Cr
+65.37% YoY
5.38%
+1.4pp YoY
₹3.37
On a consolidated basis (primary), Exide posted revenue of ₹5,291.87 Cr (+21.25% YoY, -4.28% QoQ) and PAT of ₹287.14 Cr (+65.37% YoY, -18.26% QoQ). Standalone PAT grew faster at ₹386.45 Cr (+75.08% YoY, matching the company's own press release), a divergence of roughly 10 percentage points from the consolidated growth rate — explained by Exide Energy Solutions (EESL), the lithium-ion cell subsidiary, which posted a ~₹24.8 Cr net loss this quarter (per the auditor's limited review note) as it ramps its newly commissioned gigafactory. Readers should treat the consolidated figure as the primary read since it captures this drag; neither the current nor year-ago quarter carried any exceptional item, so both YoY comparisons are clean and unadjusted.
Q2 FY-2027 vs prior quarters
Margins expanded YoY on both measures: consolidated NPM rose to 5.38% from 3.93% (+145bps) and operating margin to ~10.6% from 8.97% (+165bps); standalone EBITDA margin (company-reported) gained 270bps YoY to 12.1%. Management credited cost-optimisation initiatives and calibrated price increases for absorbing input-cost pressure — Lead LME and antimony costs stayed elevated YoY on prolonged geopolitical disruption, and MD Avik Roy noted that even the sequential softening in these commodity prices could not fully flow through because of a weaker rupee. Sequentially, both revenue (-4.28%) and PAT (-18.26%) eased from Q1 FY27, which had been a seasonally stronger summer quarter for UPS/inverter demand (standalone Q1 PAT had itself risen 27.1% YoY) — so the QoQ dip reads as normalisation rather than a trend break, and the YoY print remains the more meaningful signal.
The stock went into the print at ₹366.9, down 9.5% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters.
FY27 ₹1,400 Cr lithium capex approved, 25–30% plant utilization targeted. Core business mid-double-digit growth momentum. No full-year revenue guidance given; high base effects in H2 expected post-GST boom.
— This quarter: met
No verifiable Street consensus specific to this quarter could be confirmed via search, so the comparison is marked unknown rather than guessed. Against the company's own prior commentary — "core business mid-double-digit growth momentum," with no formal full-year revenue guidance — standalone topline growth of 20.3% YoY comfortably clears that bar, a beat on the only guidance leg management had set. On the ₹1,400 Cr FY27 lithium capex plan and 25-30% utilisation target flagged last quarter, Exide stayed on schedule: EESL commissioned its 6 GWh cell gigafactory in Bengaluru on 23 September 2026 (scalable to 12 GWh), taking cumulative equity infused into the subsidiary to ₹5,352 Cr (₹550 Cr added this half) — but utilisation itself remains undisclosed, as the facility is still in a pre-revenue phase management describes as "stabilising the lines, improving yields and completing customer qualifications," so that leg is on-track rather than confirmed. Segment momentum was broad-based: Automotive OEM grew over 25% YoY for a fourth straight quarter (100% share-of-business wins on MG's Hector Tomahawk and Tata's Aeris CNG), 2W/4W replacement sustained double-digit growth for a fourth straight quarter, and Home Inverters/Solar and Exports each grew 20%+ YoY.
W1
H2 FY27 base effect: management flagged last year's post-GST demand surge as a high base — watch whether YoY growth decelerates from this quarter's 21%+ revenue pace
W2
EESL ramp-up: utilisation progress toward the 25-30% target and whether the subsidiary's quarterly loss (~₹25 Cr this quarter) narrows as line stabilisation and customer qualification complete
W3
Input-cost/currency pass-through: management said softer Lead LME/antimony prices were offset by rupee weakness in Q2 — watch whether the benefit flows through if the rupee stabilises